PRINCETON, N.J. — August 13, 2025 — Leads & Copy — PDS Biotechnology Corporation (Nasdaq: PDSB) reported a net loss of $9.4 million for Q2 2025, or $0.21 per share, compared to $8.3 million, or $0.23 per share, for Q2 2024. The company highlighted progress in its VERSATILE-003 Phase 3 clinical trial, evaluating PDS0101 in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
Frank Bedu-Addo, Ph.D., President and CEO, noted the productivity of the quarter, including data from the VERSATILE-002 trial, suggesting potential durable clinical benefit of PDS0101. Three abstracts on PDS0101 were presented at the 2025 ASCO annual meeting.
R&D expenses were $4.2 million for the quarter, down from $4.5 million in 2024. General and administrative expenses decreased to $3.4 million from $4.2 million. The company’s cash balance was $31.9 million as of June 30, 2025.
A conference call is scheduled for today at 8:00 a.m. Eastern Time.
Investor Contact: Mike Moyer, LifeSci Advisors, Phone +1 (617) 308-4306, Email: mmoyer@lifesciadvisors.com
Media Contact: David Schull, Russo Partners, Phone +1 (858) 717-2310, Email: david.schull@russopartnersllc.com
Source: PDS Biotechnology
